Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Drug Discovery
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 344510
Licensor grants an exclusive license. with the right to grant sublicenses through multiple tiers of Sublicensees. to use the Licensor Trademarks on or in connection with the commercialization of the Licensed Product in the Licensed Territory in the Licensed Field.
The trademark is ESTYBON.
Rigoscrtib is a novel targeted anti-cancer compound currently in a Phase Ill study for the treatment of a group of rare hematologic malignancies called /.1yelodysp!astic Syndromes (MOS) and in a Phase II/Ill study for pancreatic cancer.
The Compound means the substance that is a sodium salt of (E)-2,4,6-trimethoxystyryl-3 carboxymethylamino-4-methoxybenzyl sulfone, or any Derivative/Improvement thereof.
The Patents include among others
Amino substituted sulfones treating proliferative disorders, and,
Composition and Methods for Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia.
IPSCIO Record ID: 344515
Licensee shall have full responsibility for all commercialization activities for the Commercial Product.
Licensor grants an exclusive license, with the right to grant sublicenses through multiple tiers of Sublicensees, to use the Licensor Trademarks on or in connection with the commercialization of the Licensed Product in the Licensed Territory in the Licensed Field.
Within a reasonable time after the Effective Date, but in no event later than the first anniversary thereof, Licensee shall inform Licensor in writing if Licensee elects to use the Licensor Trademarks in connection with the commercialization of the Licensed Product in the Licensed Territory.
The Compound means the substance that is a sodium salt of (E)-2,4,6-trimethoxystyryl-3 carboxymethylamino-4-methoxybenzyl sulfone, or any Derivative/Improvement thereof.
The Trademark is Estybonâ„¢.
The patents include, but are not limited to
Substituted Styrylbenzyl Sulfones for Treating Proliferative Disorders, and,
Composition and Methods for Treatment of Myelodysplastjc Syndrome (MDS) and Acute Myeloid Leukemia.
Additional Indication means any indication for Licensed Products other than r/r MDS, Frontline MDS, Frontline Pancreatic or Ovarian Cancer.
IPSCIO Record ID: 369259
Licensor does grant a non-exclusive license to use the Licensor Trademarks.
Pacritinib Citrate means the citrate salt of 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene.
The trademarks are CTI and other Licensor owned trademarks.
Pacritinib is a macrocyclic Janus kinase inhibitor that is being developed for the treatment of myelofibrosis.
The Licensed Field means all human therapeutic indications. The Initial Indication means Myelofibrosis.
Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body's normal production of blood cells. Myelofibrosis causes extensive scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue.
IPSCIO Record ID: 26488
IPSCIO Record ID: 245950
The patents are regarding manufacturing method and Polymorphism and combination use.
The Product shall mean any therapeutic or preventative pharmaceutical products containing the Compound as an ingredient.
The Compound shall mean the compound known as TM-411 (Tamibarotene), and any parts, analogs and derivatives thereof.
The trademark shall mean OSALEUKIN.
Field 2 shall mean the pharmaceutical prevention or treatment in human hematological malignancies, including but not limited to Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia (CMMoL), Chronic Myelocytic leukemia (CML) and Acute myelocytic leukemia (AML) and solid tumor indications except Hepatocelluar carcinoma (HCC). Field shall collectively mean Field 1 and Field 2.
